My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
COMPLIANCE INFO_2020
Environmental Health - Public
>
EHD Program Facility Records by Street Name
>
M
>
MAIN
>
1172
>
2200 - Hazardous Waste Program
>
PR0538664
>
COMPLIANCE INFO_2020
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
6/23/2020 8:45:02 AM
Creation date
6/4/2020 8:32:41 AM
Metadata
Fields
Template:
EHD - Public
ProgramCode
2200 - Hazardous Waste Program
File Section
COMPLIANCE INFO
FileName_PostFix
2020
RECORD_ID
PR0538664
PE
2220
FACILITY_ID
FA0000833
FACILITY_NAME
Save Mart #386
STREET_NUMBER
1172
Direction
N
STREET_NAME
MAIN
STREET_TYPE
St
City
Manteca
Zip
95336
APN
218-210-100-000
CURRENT_STATUS
01
SITE_LOCATION
1172 N Main St
P_LOCATION
04
P_DISTRICT
003
QC Status
Approved
Scanner
SJGOV\dsedra
Tags
EHD - Public
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
151
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
1 4.Lt. Defendant shall keep a record with the information required by section 66273.39, <br /> 2 subdivisions (a)(1)—(3), of each shipment, if any, of universal waste received at any California <br /> 3 Facility, as provided by Title 22 of the California Code of Regulations section 66273.39. <br /> 4 4.l.u. Defendant shall comply with the California Medical Waste Management Act, Health <br /> 5 and Safety Code sections 117600, et seq. <br /> 6 4.1.v. Defendant shall not knowingly cause to be deposited,without the permission of the <br /> 7 owner, any hazardous substance upon the land of another, in violation of Penal Code section <br /> 8 374.8, subdivision(b). <br /> 9 4.2 Reverse Distribution of Pharmaceuticals <br /> 10 4.2.a. By November 1, 2013, Defendant shall initiate work with appropriate stakeholders <br /> 11 from business, including through retail trade associations, and directly or indirectly those from <br /> 12 government, including the U.S. Environmental Protection Agency,the U.S. Food and Drug <br /> 13 Administration,DTSC and California Department of Public Health, and thereafter either directly <br /> 14 or through trade associations or informal coalitions of interested parties, undertake to promote <br /> 15 federal regulatory reform regarding the proper management of non-dispensable pharmaceuticals, <br /> 16 including over-the-counter medications,through reverse distribution. Such work shall include <br /> 17 coordination and communication with national retail trade associations. Progress on such work <br /> 18 shall be included in the status reports required by Paragraph 22 below. <br /> 19 4.2.b. During the term of this Final Judgment,the People shall only pursue a violation of <br /> 20 this Final Judgment or applicable law regarding the reverse distribution of such non-dispensable <br /> 21 phannaceuticals if Defendant has failed to demonstrate reasonable diligence, given Defendant's <br /> 22 size, capacity and scope in performing work on the federal regulatory reform described in <br /> 23 subparagraph 4.2.a above. Nothing herein shall prevent the People from pursuing appropriate <br /> 24 enforcement of this Final Judgment or applicable law regarding the reverse distribution of- <br /> 25 <br /> £25 1. Non-dispensable pharmaceuticals for acts or omissions occurring on or <br /> 26 after ninety(90) days following receipt by Defendant of written notice as provided by <br /> 27 Paragraph 8 of their intent to do so, or; <br /> 28 <br /> 8 <br /> STIPULATION FOR ENTRY OF FINAL JUDGMENT AND PERMANENT INJUNCTION <br />
The URL can be used to link to this page
Your browser does not support the video tag.